Truist Financial Corp Sells 37,080 Shares of Amgen Inc. $AMGN

Key Points

• Truist Financial Corp trimmed its Amgen stake by 7.9%, selling 37,080 shares and now holds 434,301 shares (~0.08%) valued at about $142.15 million; overall institutional ownership is ~76.5% and several large funds (Vanguard, Capital World, Capital International, Invesco) increased positions.
• Amgen beat Q1 estimates, reporting $5.15 EPS (vs. ~ $4.77 consensus) and $8.62 billion in revenue (+5.8% YoY), and set FY2026 EPS guidance of $21.70–$23.10, which is generally viewed as roughly in line with expectations.
• Dividend and outlook: Amgen declared a $2.52 quarterly dividend (annualized $10.08, ~3.1% yield); analyst views are mixed—Goldman raised its target to $425 while the consensus rating is "Hold"—and the stock faces regulatory risk tied to proposed FDA action on Tavneos.

Truist Financial Corp trimmed its position in Amgen Inc. (NASDAQ:AMGN - Free Report) by 7.9% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 434,301 shares of the medical research company's stock after selling 37,080 shares during the period. Truist Financial Corp owned about 0.08% of Amgen worth $142,151,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in Amgen by 1.8% in the 4th quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company's stock valued at $17,949,296,000 after buying an additional 961,975 shares during the last quarter. Capital International Investors boosted its position in Amgen by 1.5% in the 3rd quarter. Capital International Investors now owns 19,192,995 shares of the medical research company's stock valued at $5,414,296,000 after buying an additional 282,219 shares during the last quarter. Capital World Investors boosted its position in Amgen by 11.5% in the 3rd quarter. Capital World Investors now owns 18,795,474 shares of the medical research company's stock valued at $5,303,578,000 after buying an additional 1,935,876 shares during the last quarter. Capital Research Global Investors boosted its position in Amgen by 2.7% in the 3rd quarter. Capital Research Global Investors now owns 4,731,290 shares of the medical research company's stock valued at $1,335,168,000 after buying an additional 122,631 shares during the last quarter. Finally, Invesco Ltd. boosted its position in Amgen by 6.6% in the 3rd quarter. Invesco Ltd. now owns 4,467,287 shares of the medical research company's stock valued at $1,260,668,000 after buying an additional 277,031 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors.

Amgen Price Performance

NASDAQ:AMGN opened at $329.82 on Monday. Amgen Inc. has a 12-month low of $261.43 and a 12-month high of $391.29. The company has a quick ratio of 0.90, a current ratio of 1.26 and a debt-to-equity ratio of 5.65. The firm has a market capitalization of $178.00 billion, a P/E ratio of 22.95, a P/E/G ratio of 3.24 and a beta of 0.44. The stock's fifty day simple moving average is $358.07 and its 200-day simple moving average is $341.12.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The business had revenue of $8.62 billion for the quarter, compared to analyst estimates of $8.58 billion. During the same period last year, the company earned $4.90 EPS. The firm's revenue was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Equities research analysts expect that Amgen Inc. will post 22.28 earnings per share for the current year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be given a $2.52 dividend. This represents a $10.08 annualized dividend and a dividend yield of 3.1%. The ex-dividend date is Friday, May 15th. Amgen's dividend payout ratio (DPR) is currently 70.84%.

Analyst Upgrades and Downgrades

A number of research analysts have commented on AMGN shares. Wall Street Zen lowered Amgen from a "buy" rating to a "hold" rating in a research report on Saturday, April 25th. Wells Fargo & Company increased their price objective on Amgen from $375.00 to $390.00 and gave the company an "equal weight" rating in a research report on Thursday, March 19th. The Goldman Sachs Group increased their price objective on Amgen from $415.00 to $425.00 and gave the company a "buy" rating in a research report on Friday. Mizuho increased their price objective on Amgen from $280.00 to $295.00 and gave the company an "outperform" rating in a research report on Tuesday, February 10th. Finally, Royal Bank Of Canada increased their price objective on Amgen from $360.00 to $370.00 and gave the company an "outperform" rating in a research report on Tuesday, April 7th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $357.54.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Q1 results beat expectations — AMGN reported $5.15 EPS vs. $4.73 consensus and product sales rose ~4%, with 16 drugs delivering double‑digit growth, supporting the company’s growth story. Amgen's Q1 Earnings Top Estimates
• Positive Sentiment: Bullish analyst action — Goldman Sachs reiterated a Buy and lifted its price target to $425, signaling long‑term upside from execution and pipeline momentum. Goldman Sachs Raises PT to $425
• Positive Sentiment: Other supportive analyst notes — Some firms (e.g., William Blair) reiterated Buy ratings after the quarter, highlighting confidence in the MariTide/weight‑loss program and execution. Analyst Reiterates Buy
• Neutral Sentiment: Guidance set but roughly in line — Amgen updated FY‑2026 EPS guidance to $21.70–$23.10 (consensus ~22.29), which many read as broadly in‑line rather than materially bullish. Amgen FY2026 Guidance (press release/slide)
• Neutral Sentiment: Small, mixed analyst target moves — Truist nudged its target to $327 with a Hold rating (minimal change), leaving some investors watching for clearer directional signals. Truist Raises PT to $327
• Negative Sentiment: FDA action risk — The FDA proposed withdrawing Tavneos approval after alleging clinical‑trial data issues, raising regulatory, compliance and reputational concerns that can pressure the stock. FDA Tavneos Proposal Coverage
• Negative Sentiment: Investor apprehension over strategy/timing — Some market commentary framed the quarter as “generally in‑line” and expressed concern about Amgen’s aggressive push into obesity (MariTide) and the near‑term profit impact, contributing to selling pressure. Investor Reaction to MariTide Expansion

Amgen Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.